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Abstract 
BACKGROUND/PURPOSE: Pain management for hip fracture patients in the time before 
surgery is crucial. Literature highlights the success of local, single injection nerve blocks to aid in 
preoperative pain management. A local hospital implemented a preoperative, single injection nerve 
block protocol in March 2018. This quality improvement project investigated: (1) organization 
protocol compliance, and (2) if the preoperative single injection nerve block protocol reduces hip 
fracture pain, use of systemic opioid analgesics, decreases incidence of adverse opioid effects, and 
reduces cost of care. SUBJECTS: Patients ages 18 and older admitted with the primary diagnosis 
of an operable isolated hip fracture (n=100). METHODS: Data measures were extracted from the 
electronic health records and the trauma registry and were entered into REDCap encrypted 
software. ANALYSIS: Data was analyzed using SAS statistical software to verify whether the 
intervention was successful in meeting cost, quality, and compliance measures. RESULTS: 
Results were not statistically significant in reducing oral and intravenous narcotic use before 
(p=0.80; p=0.39) and after (p=0.23; p=0.10) surgical correction, nor was there statistically 
significant change in adverse effects (p=0.10) and length of stay (p=0.90). However, there was a 
statistically significant reduction in preoperative pain levels following nerve block administration 
(p<0.0001).Protocol compliance was 66% over seven months. CONCLUSION: The results of this 
project were consistent with the literature; nerve block injection may reduce preoperative pain for 
patients with an operable hip fracture. Further investigation is needed to determine if narcotic use 
and length of stay could be impacted if time variability in nerve block administration were reduced 
and if protocol compliance were increased.  
 Keywords: hip fractures, preoperative period, nerve block, and pain management 
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An Evaluation of a Nerve Block Protocol in Hip Fracture Patients 
Introduction 
Hip fractures are a debilitating injury associated with acute pain, functional impairment, 
increased morbidity and mortality, and substantial financial burden (Centers for Disease Control 
and Prevention [CDC], 2016a; Riddell, Ospina, & Holroyd-Leduc, 2016; Sanzone, 2016). For 
those ages 65 and older, this type of injury is one of the most common reasons for admission to an 
orthopedic unit, resulting in over 300,000 hospitalizations annually (CDC, 2016a; Freeman & 
Clarke, 2016; HCUPnet, 2012). One of the most important aspects of surgery is pain management, 
as most hip fracture patients experience moderate to severe pain (Sanzone, 2016). Effective pain 
control is associated with early postoperative ambulation and functional recovery, decreased length 
of stay, decreased thrombotic events, and improved patient satisfaction (Wang, Sun, Wang, Hao, 
2017).  
Yet, optimal pain control is typically underutilized in hip fracture care (Haslam, Lansdown, 
Lee, van der Vyver, 2013). There is limited research and expert agreement on the most effective 
approach to controlling preoperative hip fracture pain. The current standards of practice reflect an 
opioid model of analgesia. However, systemic opioid use in the preoperative phase is associated 
with significant side effects, such as nausea, vomiting, constipation, confusion or delirium, 
drowsiness, and respiratory depression (Freeman & Clarke, 2016; Sanzone, 2016; Wang et al., 
2017).  
Additionally, mismanaged preoperative pain is associated with increased cost of care, 
prolonged rehabilitation, patient dissatisfaction, and overall increased risk of morbidity and 
mortality (Riddell et al., 2016; Sanzone, 2016). Therefore, early effective preoperative pain 
management represents a key opportunity for patient care improvement. 
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An abundance of literature supports the use of nerve blocks as an effective adjunct for 
localized, preoperative pain control (Morrison, et al., 2016; Sanzone, 2016; Riddell et al., 2016; 
Ritcey, Pageau, Woo, & Perry, 2016). A nerve block is an injection of a local anesthetic around a 
nerve. In the case of a hip fracture, the injection would be localized to one of the branches of the 
lumbar plexus. The nerve block relieves pain regionally by interrupting pain signal transmission to 
the central nervous system (Wang et al., 2017). Common orthopaedic nerve blocks include a psoas 
compartment block, a femoral block, fascia iliaca compartment block, or combined nerve blocks. 
The techniques of administering a local nerve block include the landmark method, a nerve 
stimulator, or an ultrasound (Guay, Parker, Griffiths, & Kopp, 2017). These nerve blocks then 
target pain locally, which reduces systemic side effects of traditional narcotic use. Side effects may 
include injection site hematoma, nerve damage, block failure, and local anesthetic toxicity.  
The orthopedic physicians at XXX decided to implement a standardized protocol where all 
individuals admitted with a primary diagnosis of an isolated hip fracture would receive a 
preoperative localized, single injection nerve block. This standardized protocol was developed by 
the orthopaedic clinical nurse specialist (CNS) in December of 2017. It was enacted officially in 
March 2018 to improve hip fracture pain management from the point of emergency department 
admission to the operating room. The purpose of this quality improvement is therefore to 
determine whether or not the nerve block protocol will reduce preoperative pain, narcotic 
medication use, narcotic-related adverse effects, and inpatient care cost in operable hip fractures.  
Assessment of the Organizational  
Framework for Assessment 
 The Burke-Litwin Model of Organizational Performance and Change (1992) is a causal 
model describing the twelve interconnected factors of organizational change (see Appendix A). The 
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Burke-Litwin Model (1992) is divided into microscopic, or transactional factors, and macroscopic, 
or transformational factors. Microscopic, or transactional, variables include work unit climate, 
management practices, structure, task and individual skills, motivation, systems, individual needs 
and values, and individual and organizational performance (Burke & Litwin, 1992). Macroscopic, 
or transformational, variables include external environment, leadership, mission and strategy, and 
organizational culture (Burke & Litwin, 1992). This model has content validity and internal 
reliability, which means that it consistently measures what it purports to measure across all of its 
constructs (Burke & Litwin, 1992; Stone, 2015). 
Ethics and Protection of Human Subjects 
 Prior to data collection and analysis, an application was submitted to the XXX Institutional 
Review Board. No project activites will commence prior to review and approval by the Board. The 
purpose and scope of this project was limited to evidence-based quality improvement. The data 
used for analysis was de-identified and coded when pulled from the patient chart and transferred to 
a data collection tool. No research consent was needed for this quality improvement project, as it 
entails retrospective data collection. All members of the team have completed human subjects 
protection training via the Collaborative Institute Training Initiative and their interactions with 
patient records were guided accordingly. 
Stakeholders 
Key stakeholders include those individuals or groups entrenched and invested in the 
organization (Moran et al., 2017). Consulting with people that have skill sets, experience, and 
perspectives provide valuable insight to the organization practices. Within the context of this 
project, the key stakeholders include the healthcare providers and residents (orthopeadics, 
emergency medicine, internal medicine, and anesthesia), nurse practitioners, physician assistants, 
the rapid response team, patients, registered nurses (RNs), unit leadership (ED, PACU, OR, and 
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OU managers), and each unit’s clinical nurse specialists (CNSs) and leaders (CNLs). The 
orthopaedic physicians and residents order pain medications before and after surgery and perform 
the surgeries. RNs administer the pain medications, assess and monitor the patient response, and 
document pain scores before, during, and after surgery. This helps ensure accurate and timely 
documentation of pain treatment. Patients receive the pain medication as well as undergo surgery 
for their hip fractures. Unit leadership and the CNSs monitor unit processes, satisfaction, and 
compliance with organization policy, quality, and standards. Therefore, all are considered key 
stakeholders in this organizational assessment.  
SWOT 
A SWOT analysis is a tool used to evaluate the current state of an organization. The 
acronym SWOT stands for ‘strengths’, ‘weaknesses’, ‘opportunities’, and ‘threats’ (Gurel & Tat, 
2017). Threats refer to situations or entities that may endanger or impede the organization’s 
functions. Opportunities refer to situations, resources, or entities that an organization may use 
advantageously and/or to counteract threats (Gurel & Tat, 2017). Internal strengths include 
advantageous and unique characteristics that differentiate the organization from its competitors. A 
weakness, though, refers to an organization’s lack of situations, resources, functions, or abilities, 
which contribute to inefficient or ineffective functioning (Gurel & Tat, 2017).  
This analysis assessed an organization’s external threats and opportunities as well as its 
internal strengths and weaknesses. A SWOT analysis was conducted to assess the current state of 
hip fracture pain control across the ED, PACU, OR and OU (see Appendix B). The awareness 
gleaned from this analysis can help the organization reach preoperative hip fracture pain 
management goals (Gurel & Tat, 2017).  
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 Strengths of the organization include leadership training in Lean Six Sigma, a culture of 
process improvement, organization-wide teamwork, Magnet designation, The Joint Commission 
(TJC) orthopaedic certifications, Hospital Quality Awards, Clinical Quality Awards for joint 
replacements, the presence of an orthopaedic nurse navigator, and joint repair preparation classes 
(American Nurses Association, American Nurses Credentialing Center, & American Nurses 
Foundation, 2018; GoLeanSixSigma, 2016; Healthgrades, 2018; TJC, 2018). Major weaknesses of 
the organization are a lack of standardized pain management for hip fractures and use of variable 
orthopaedic order sets for patients. Other weaknesses include an inability for providers to regularly 
meet face to face, anesthesiology staffing, new provider unfamiliarity, transitions of care at 
discharge, and utilizing the same diagnostic related group (DRG) codes for hip fractures and 
elective hip arthroplasty.  
 Opportunities for the organization include decreasing the unnecessary use of opioids, 
implementing new evidence in the form of preoperative nerve blocks, and the new orthopaedic 
group merger (Morrison, et al., 2016; Sanzone, 2016; Riddell et al., 2016; Ritcey, Pageau, Woo, & 
Perry, 2016). Additionally, another opportunity includes gleaning insight from sister organizations 
with similar protocols. Threats to the organization are competition from other local hospitals with 
already established nerve block protocols, local branding from other hospitals, insurance company 
preference, and Centers for Medicaid and Medicare reimbursement measures (CMS, 2018).  
Clinical Practice Question 
The organizational assessment and SWOT analysis suggest that the already implemented 
nerve block protocol can positively impact hip fracture care. The clinical practice questions are: (1) 
Does this preoperative, single-injection nerve block, which serves as a pain management adjunct, 
reduce preoperative reports of pain, overall administration frequency of opioid analgesic/morphine 
equivalents, incidence of opioid-associated adverse effects, and costs of inpatient care in hip 
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fracture patients over an 8 month period compared to standard preoperative opioid analgesic 
therapy/morphine equivalents? (2) What is the protocol compliance rate? 
Review of the Literature 
Method 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guideline served as the framework for this review (Moher, Liberati, Tetzlaff, Altman, & PRISMA 
Group, 2009). A comprehensive search was conducted in the PubMed, Cochrane Library, 
CINAHL, and Web of Science databases and was limited to reviews in the English language from 
2008 to 2018. Keywords were hip fractures, preoperative period, nerve block, and pain 
management. The search expertise of an experienced librarian was also utilized. 
Inclusion and Exclusion Criteria  
 Population. Included were sample populations that were at least 16 years of age and older 
with an acute a hip fracture. Studies were excluded if the sample included people younger than 16 
years old, if subjects underwent an elective total hip arthroplasty or revision, subjects with mid-
shaft or unspecified femoral fractures, and subjects that were deemed non-operable.  
 Intervention. The intervention is the administration of a single injection nerve block 
(femoral [FNB], psoas compartment, fascia iliaca compartment [FICB], 3-in-1) prior to surgery for 
a hip fracture as an adjunct to standard preoperative opioid analgesics. Both nerve stimulator, 
landmark, and ultrasound guided (USG) forms of administration were included in order to capture 
more robust evidence. Types of blocks (ropivacaine, bupivacaine, etc.) were included in the search 
and not separately evaluated. Studies were excluded if the nerve block administration occurred 
right before, during or after surgery, if a continuous nerve block catheter was placed, if the subject 
also received an epidural or spinal anesthetic in conjunction with the nerve block, or if nerve block 
administration occurred for a different injury.  
FINAL DEFENSE  11
   
 
 
 Comparison. The primary comparisons were those patients treated with just standard 
administration of preoperative opioid analgesic/morphine equivalents for pain control. Studies 
were excluded if the comparison was a non-steroidal anti-inflammatory medication, 
acetaminophen, or epidural/spinal anesthesia. 
 Outcome. Primary outcomes consisted of acute pain management, frequency of opioid 
pain medication use, and overall opioid medication use. Secondary outcomes included delirium, 
opioid or nerve block adverse side effects, mortality, functional status, and length of stay. Studies 
that failed to address at least one of these outcome measures were excluded.  
Search Outcomes 
 The initial search using the aforementioned keywords yielded 62 articles across 4 databases 
(see Appendix C). Papers were removed if they were duplicates, did not meet the inclusion criteria, 
and did not meet content criteria. The final 10 papers evaluated adults who presented to the 
hospital for a hip fracture (see Appendix D).  
Intervention and Comparison Characteristics 
 Each review compared administration of a single injection nerve block (femoral [FNB], 
psoas compartment, fascia iliaca compartment [FICB], 3-in-1) prior to surgery for a hip fracture 
alone or as an adjunct to standard preoperative opioid analgesics. The most common medication of 
comparison was with morphine (oral, intramuscular, or intravenous), followed by fentanyl and 
alfentanil. Each study included either a nerve stimulator, landmark, or USG form of 
administration, although the USG technique recently emerged as the gold standard (Scurrah et al., 
2018). Across studies, administration of preoperative nerve blocks included trained ER physicians, 
orthopaedic surgeons, anesthesiologists, paramedics, and junior physicians.  
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Measures 
 The ten studies/reviews focused primarily on the efficacy preoperative regional nerve 
blocks. The Visual Analog Scale (VAS), Verbal Rating Scale (VRS) and the Numeric Rating Scale 
(NRS) were the primary tools used to measure and report differences in pain. Changes in pain 
scores on the VAS, VRS, or NRS was considered significant if P<0.05 at a 95% confidence 
interval (CI). Another outcome measure included safety (10 studies/reviews), which was defined 
as the frequency of adverse events stemming from either the intervention or comparison group. 
The reviews also reported on the resultant reduction in opioid analgesic use (9 studies/reviews), 
which was reported in milligrams. Finally, the 1 review reported on the time to the next opioid 
analgesic dose following regional nerve block administration, which was recorded in minutes. 
Results 
  Efficacy of Regional Nerve Blocks. The three systematic reviews demonstrated reductions 
in preoperative hip fracture pain for the FNB, FICB and 3-in-1 nerve block (About-Setta et al., 
2011; Riddell et al., 2016; Ritcey et al., 2016). Two reviews concluded that the evidence supports 
regional nerve blocks as an effective method in reducing pain compared to standard opioid care. 
Only one single injection study did not favor regional block efficacy, but pre-block pain scores 
were significantly higher in this group (Guay et al., 2017). The two combined systematic reviews 
and meta-analyses found significant reductions in preoperative hip fracture pain associated 
movement and positioning. However, acute pain was variable or not therapeutically different at 
rest (Fadhlillah & Chan, 2017; Steenberg & Miller, 2018).  
The integrative review evaluated the current care continuum in the ED for hip fracture 
patients. The single randomized controlled trial deemed high quality evaluated preoperative FICB 
to the control group: systemic morphine combined with a placebo injection mimicking an FICB. 
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The study (n=48) found static, or resting, pain (P<0.01) and dynamic, or moving, pain (P=0.02) 
relief superior in the FICB group compared to the morphine and placebo FICB group (Wennberg 
et al., 2018). The narrative review evaluating eight randomized controlled trials found that regional 
nerve blocks reduce hip fracture pain on movement within 30 min of block placement (Scurrah et 
al., 2018). Additionally, FICB, FNB, psoas compartment, and combined nerve block provided 
superior analgesia to placebo or ‘standard care’ in hip fractures (Scurrah et al., 2018).  
 In the AAOS (2014) review, five out of the six (n=593 patients) high strength studies 
evaluated preoperative pain management. The sixth study investigated preoperative and 
postoperative pain. VAS scores indicated significant reduction in reported preoperative pain in five 
out of the six studies and nonsignificant reduction of pain in the other study (Mean preoperative 
VAS score of placebo vs. FICB: 68.2 vs. 61.4, P=0.59) (AAOS, 2014). 
 The single randomized controlled trial (n=266) evaluated the effect of FNB and opioids 
(n=129) to conventional opioid treatment (n=137) on preoperative pain (VAS) and preoperative 
opioid consumption (Unneby et al., 2017). Self-rated and proxy VAS pain scores decreased from 
baseline to 12 hours in intervention group versus the control (P<0.001 and P=0.003, respectively) 
(Unneby et al., 2017).  
 Safety. The clinical practice guideline, the four systematic reviews, the randomized 
controlled trial, and the integrative review found no major immediate complications, such as 
adverse toxicity or persistent paresthesia, for FNB, FICB, or 3-in-1 blocks (AAOS, 2014; About-
Setta et al., 2011; Guay et al., 2017; Riddell et al., 2016; Ritcey et al., 2016; Unneby, 2017; 
Wennberg et al., 2018).  
 The two combined systematic reviews and meta-analyses also evaluated safety of single 
injection nerve blocks in preoperative hip fracture pain. In the review and analysis by Fadhlillah & 
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Chan (2017), the FICB group had reduced analgesia breakthrough (n=57 vs. n=73), reduced 
drowsiness/sedation (n=1 vs. n=22), reduced desaturation (n=0 vs. n=4), and reduced nausea and 
vomiting (n=3 vs. n=7) compared to standard preoperative analgesia. Both groups reported 
localized bruising (n=3), though (Fadhlillah & Chan, 2017). In the review and analysis by 
Steenberg & Miller (2018), there was a 1.7% incidence rate of hematoma at the injection site.  
The narrative review by Scurrah et al. (2018) found one study where the inpatient mortality 
with the regional nerve block was 5.5% versus 15% (P=0.0024) in the standard care control group. 
There was no statistically significant difference in cardiac complications, deep vein thrombosis, 
pulmonary embolism, nausea and vomiting, respiratory infection, stroke, surgical wound infection, 
or urinary tract infections with regional nerve blocks compared to standard preoperative hip 
fracture pain management (Scurrah et al., 2018).  
In terms of safety by administration, the narrative review also found that junior staff, 
paramedics, and new residents can be trained to effectively administer nerve blocks without 
increase in complications (Scurrah et al., 2018). The AAOS (2014) clinical practice guidelines for 
hip fractures also reports that the type of administering provider (emergency physicians, 
anesthesiologists, orthopaedic surgeons) did not compromise patient safety.   
 Reduction in opioid use. Three of the systematic reviews, the narrative review, and one of 
the combined systematic review and meta-analysis found less opioid consumption in the 
preoperative nerve block intervention group compared to the opioid control group (Abou-Setta et 
al., 2011; Guay et al., 2017; Ritcey et al., 2016; Scurrah et al., 2018; Steenberg & Miller, 2018). 
However, Ritcey et al. (2016) were unable to conclude whether reduced IV opiate use also resulted 
in reduced adverse effects due to under-reporting in most of the studies.   
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 Unneby et al. (2017) found that the FNB and opioid intervention group received 
significantly less opioids than the control group (Intravenous: 2.3 + 4 mg vs. 5.7 + 5.2 mg, 
P<0.001; Oral: 2.1 + 4.1 mg vs. 3.6 + 6.4 mg, P=0.017). Additionally, patients with dementia in 
the intervention group received less intravenous opioids compared to the control group (2.1 + 3.3 
mg vs. 5.8 + 5 mg, P<0.001) (Unneby et al., 2017).  
Delay in additional opioid use. Steenberg & Miller (2018) analyzed two studies 
comparing the need for additional opioids in the FICB group versus the opioid control group in 
preoperative hip fracture patients. In one study, the FICB group waited an average of 245 minutes 
(95% CI: 2055, 285) before requesting another opioid dose compared to the opioid control group, 
which waited an average of 145 minutes ((95% CI: 14.9, 275) (P=0.12)). The other study reported 
similar findings for the FICB group, which waited an average of 516 minutes (95% CI: 437, 594) 
compared to 270 minutes in the opioid control group ((95% CI: 189, 351) (P<0.01)). In total, the 
FICB group waited longer for first request of additional analgesia compared to the opioid control 
group (SMD= 0.93 (95% CI: 0.02,1.84) (P=0.05)) (Steenberg & Miller, 2018). 
Discussion of Evidence to be Used for Project 
A key theme in this review is that preoperative pain control for hip fractures can be 
improved. Single injection nerve blocks as a solitary intervention or as an adjunct to opioids 
compared to standard preoperative opioid care offer a promising solution to this problem. 
Although four of the reviews each report that only one study has a low risk of reporting bias, all 
ten studies included in this review conclude overall that single injection, regional nerve blocks are 
at least as effective, if not superior, to standard opioid analgesia in reducing hip fracture pain.  
About-Setta et al. (2011) concludes that there is a moderate level of evidence supporting 
use of nerve blocks in hip fractures, but that more rigorous studies will help provide definitive 
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guidelines. However, the AAOS (2014) clinical practice guidelines give a strong recommendation 
for the use of preoperative regional analgesia. Additionally, all ten studies report that the use of 
regional nerve blocks in hip fractures is relatively safe. However, the authors of each review cite 
the underreporting of adverse events as an issue that should be more transparent in study results. 
The other eight reviews provided evidence that supported the ability of single injection 
regional nerve blocks in reducing additional preoperative opioid consumption. These results are 
promising, given the substantial side effects associated with opioid consumption. One review 
reported on the delay in time associated with additional opioid doses following administration of 
the FICB compared to the opioid control groups (Steenberg & Miller, 2018). These two studies 
were part of the meta-analyses, which conveys a high level of evidentiary support. Despite low 
heterogeneity of the p-value, the authors caution readers to consider study heterogeneity. 
Limitations  
 The review presents several limitations. In terms of the reviews, the small sample sizes, 
heterogeneity of study methodology, and moderate to high reporting bias should all be considered 
when weighing the evidence. Additionally, the overall evidence level supporting regional nerve 
blocks in preoperative hip fracture pain is moderate. Limitations of the DNP student may include 
search methods that could have eliminated pertinent articles.  
Conclusion 
 Use of opioid analgesics remains a common practice in pre-operative hip fracture 
management. However, the review demonstrates the efficacy and safety of single injection 
regional nerve blocks in hip fracture patients. The overall evidence supporting nerve block use is 
moderate due to small sample sizes and study design variation, but it offers an alternative to 
current preoperative pain management practices and patient outcomes (see Appendix E). 
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Phenomenon Conceptual Model 
The phenomenon of preoperative pain management in hip fractures is best conveyed 
through the revised Theory of Symptom Management Model (Dodd, Janson, & Facione, 2001). 
Symptoms can be distressing to a patient and can pose management challenges for healthcare 
providers. This theoretical model defines a symptom as a subjective experience that conveys 
personal biopsychosocial changes. A sign, though is defined as an objective, or measurable 
component of a disease (Dodd et al., 2001). Both signs and symptoms help inform the course of 
patient care.  
However, this model primarily focuses on effectively managing active patient symptoms, 
which are based on patient perception and report. Consideration is also given to nonverbal patients 
and patients who are at risk for developing symptoms. In the revised model, there are three 
domains: the Person, Health and Illness, and the Environment (Dodd et al., 2001). The Person 
domain pertains to intrinsic variables that impact the way in which a person perceives and 
responds to the symptom experience. These include demographic, psychological, sociologic, and 
physiologic variables (Dodd et al., 2001). The Health and Illness domain includes individual risk 
factors, injuries, diseases, or disabilities. These variables also impact the symptom experience and 
a person’s desire to seek care. Conversely, the absence of signs or symptoms does not necessarily 
equate to health (Dodd et al., 2001). Finally, the Environmental domain represents an individual’s 
environment encompasses physical, social, and cultural variables. The context in which symptoms 
occur impact the symptom experience as well as the type of treatment and projected outcomes 
(Dodd et al., 2001).  
These three domains influence the three dimensions of the model: Symptom experience, 
Management strategies, and Outcomes. A symptom experience is an individual’s perception, 
assigned meaning, and response to a symptom (Dodd et al., 2001). The goal of symptom 
FINAL DEFENSE  18
   
 
 
management is to delay or avoid a negative health outcome. Components of symptom management 
include the time, method, amount, location, and purpose of an intervention designed to mitigate or 
eliminate patient symptoms (Dodd et al., 2001). Finally, the Outcomes represent the product of 
symptom experience and management. This dimension includes functional and emotional status, 
self-care, quality of life, morbidity, mortality, and cost of interventions (Dodd et al., 2001).  
Overall, this model offers a comprehensive conceptualization of symptom expression. It 
helps clinicians understand symptoms in order to select appropriate management strategies and 
assess the impact of such strategies (Dodd et al., 2001). Therefore, this model serves as the best 
lens through which to view the phenomenon of preoperative hip fracture pain (see Appendix F). 
Project Plan 
Purpose of Project and Objectives 
The orthopedic physicians at XXX decided to implement a standardized protocol where all 
individuals admitted with a primary diagnosis of an isolated, operable hip fracture would receive a 
localized, single injection nerve block. The protocol was enacted in March 2018 to safely and 
effectively manage pain for this patient population from the point of emergency department 
admission to the operating room. The purpose of this quality improvement is therefore to 
determine whether or not the preoperative nerve block protocol addresses the following objectives: 
reduced preoperative pain, reduced narcotic drug use, reduced narcotic-related adverse effects, and 
reduced potential cost of inpatient care in this population. 
Design for the Evidence-based Initiative 
The nerve block protocol was designed by the orthopaedic CNS through the 
communication of all of the key stakeholders involved in hip fracture care (see Appendix G). This 
protocol and list of responsibilities is located in the education booklets in the ED and OU for staff 
to reference. The CNS has already educated all care teams and units involved to familiarize 
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employees with the protocol and associated expectations. Anesthesiology also maintains the 
organization’s standard for educating the patient on the nerve block and clearing a patient for the 
nerve block. Feedback was collected on an ongoing basis to identify, address, and mitigate factors 
that may contribute to negative patient outcomes. For data analysis, the pre-block protocol data is 
obtained through a retrospective record review based on the aforementioned outcome indicators. 
Setting  
The organization of interest is a local West Michigan hospital that sees a full spectrum of 
patient conditions and provides a variety of services. The units involved in this proposed practice 
change, though, include the emergency department (ED), the post-anesthesia care unit (PACU), 
the surgical floor (OR), and the orthopaedic medical-surgical unit (OU). These units are integral to 
the continuum of care for hip fracture patients from time of admission to discharge. Patients 
admitted in the ED for hip fractures will typically go straight to preoperative holding on the 
surgical floor if there is an opening in the OR schedule. If not, then the patients are sent to the OU 
until there is an opening in the OR. After the procedure in the OR, the patients are held in PACU 
to monitor for anesthesia side effects, vital signs, and pain. Once the patient is deemed stable, the 
patient is transferred to the OU for postoperative care until discharge. In 2017, there were 168 hip 
fractures, of which 146 received surgical correction.    
Participants   
All patients admitted to the organization for hip fractures and are eligible for surgery from 
March 1, 2018 to December 31, 2018 were offered the nerve block as part of the established 
protocol. The pre-nerve block group included all patients admitted to the organization for hip 
fractures and underwent surgical correction from June 1, 2017 to February 28, 2018. Patients were 
excluded if their hip fracture is non-operable, for nerve block refusal, or if there is a medical 
allergy to the nerve block medication. 
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Model Guiding Implementation 
Utilization of Rosswurm & Larrabee’s Model for Evidence-Based Practice Change (1999) 
provides the best approach to effectively evaluate this preoperative nerve block protocol for hip 
fractures. This model provides a systematic process for implementing evidence-based change 
through the assistance of key stakeholders and in the context of the cultural climate. It was initially 
developed to correct the continued struggle of research utilization by practitioners (Rosswurm & 
Larrabee, 1999). This model has six steps for implementation and sustainability (see Appendix H). 
First step: Assess need for change in practice. This step involves the collection of data in 
order to identify a clinical practice problem. This organizational data is then compared to external, 
or national databases, from which care standards are established. Information is also gleaned from 
key stakeholders to substantiate the practice problem’s effect on patient care (Rosswurm & 
Larrabee, 1999).  
Second step: Link problem with interventions and outcomes. The problem must then be 
translated into a standardized nursing or clinical classification. This facilitates ease of data 
collection, analysis, and dissemination. This step then includes connecting the practice problem to 
interventions and subsequent outcome expectations (Rosswurm & Larrabee, 1999).  
Third step: Synthesize best evidence. At this step, the proposed interventions and 
outcomes are further clarified to facilitate a more specific literature review. Practitioners appraise 
the quality of the literature and level of evidence. The purpose of this step is therefore to 
investigate whether the current literature supports the need for the practice within that particular 
healthcare context (Rosswurm & Larrabee, 1999).  
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Fourth step: Design a change. Following the synthesis of evidence, practitioners may 
then construct a protocol that details the sequence of steps for the practice change. Process and 
outcome indicators will be outlined for recording and data analysis. These indicators outline staff 
actions, resources, costs, and projected patient care outcomes (Rosswurm & Larrabee, 1999).  
Fifth step: Implement and evaluate change. Implementation of the practice change must 
be accompanied by continuous monitoring, reinforcement, and openness to staff feedback. Data is 
collected for the length of the intervention trial and analyzed to verify whether the practice change 
was successful in meeting the desired outcome indicators. Staff and peer feedback, cost, and 
benefits and risks are also taken into consideration when evaluating the effectiveness of the change 
(Rosswurm & Larrabee, 1999).  
Sixth step: Integrate and maintain change. Following implementation of a pilot protocol, 
staff and organizational buy-in help produce a revised protocol for approval. Integration and 
sustainability of the practice change occurs when stakeholders are continuously informed and 
included. This enhances the acceptance and perceived feasibility of the practice change within the 
context of the organization (Rosswurm & Larrabee, 1999).  
Implementation Steps and Strategies 
Following the organizational assessment, SWOT analysis, and literature review, the goal of 
the next steps is to assess whether or not this protocol is effective in meeting the specified 
measures. In accordance with Rosswurm and Larrabee’s model (1999) and Powell et al. (2015) 
implementation strategies, steps to evaluate this nerve block protocol include the following: 
1. Build a coalition prior to implementation by November 5th, 2018. 
According to Powell et al. (2015), building a coalition refers to recruiting and building 
relationships with key stakeholders in order to partner in the implementation initiative. 
Steps to build a coalition involves: 
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• Prior cultivated relationship in April 2018 with the designated orthopaedic CNS 
that spearheaded this initiative. She serves as a liaison to the orthopeadic, 
emergency medicine, internal medicine, and anesthesia providers, the nurse 
practitioners, physician assistants, the rapid response team, unit managers (ED, 
PACU, OR, and OU managers), and the ED, PACU, and OR clinical nurse 
CNSs and CNLs. This was because the organization’s Institutional Review 
Board (IRB) was not yet granted to the DNP student. 
• The DNP student established communication and attended meetings with the 
othopaedic CNL, orthopaedic nurse navigator, the orthopaedic unit nurse 
manager, the Clinical Service Director, and the trauma CNS throughout several 
meetings in May, June, and July of 2018.  
• The DNP student met with Grand Valley State University Statistician graduate 
student in May 2018 to review excel spreadsheet for data collection.   
• The DNP student established phone and email communication with the Clinical 
Information Specialist, the information data specialist who helped facilitate data 
extraction from the patient EHR for data analysis.  
2. Submit application to Grand Valley and organization’s IRB for project approval and 
EHR access by November 9th, 2018. 
• Submission of the IRB application by this data to both organizations granted 
access to the EHR system for retrospective and real-time data collection.  
• Approval also ensured ethical oversight by the two organizations.  
• The organization already implemented the protocol in March 2018. The DNP 
student’s role therefore involved data collection, analysis, and assistance with 
possible recommendations protocol revision. 
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3. Develop an evaluation blueprint by November 9th, 2018. 
According to Powell et al. (2015), developing an evaluation blueprint includes “1) an 
aim/purpose; 2) scope of the change; 3) timeframe and milestones; and 4) appropriate 
performance/progress measures” (p. 8). Steps needed to formulate a blueprint for 
evaluating the nerve block protocol include:  
• The aim/purpose or clinical question was stated earlier. The protocol was 
already implemented in March 2018. 
• The scope of the change includes the units affected by the proposed nerve block 
protocol. These include the ED, PACU, OR, and OU. 
• The timeframe and specific data measures will be explained in later sections. 
4. Evaluation of workflow modifications pending approval of IRB access by November 
26th, 2018. Steps include:  
• The orthopaedic CNS already compiled the appropriate order sets for hip 
fracture admission, which includes the nerve block, due to the DNP student’s 
initial inability to access charts and the EHR. This, combined with the hip 
fracture care flowchart, facilitated ease of ordering and mitigate staff and 
provider confusion.  
• Monthly audits (Point 5) will determine whether the protocol is being followed 
by the staff involved in this protocol.  
5. Perform weekly audits of the outcome measures starting December 1, 2018, pending 
Grand Valley State University and the organization’s IRB approvals. 
Powell et al. (2015) define audits as a process of collecting and summarizing clinical 
data acquired over a designated time period. Providing clinicians and administrators with 
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this data will facilitate real-time evaluation and monitoring of the protocol success in case 
protocol revisions must be made. Steps include:  
• Meet with Clinical Information Specialist who will help direct the DNP student 
on how to extract the data appropriate for the project. Meetings and/or phone 
call correspondence occurred on the same day each month that the DNP Student 
was present at the organization to perform the chart audits.  
• Monthly audits occurred from the time of IRB approval until Janurary 2018 in 
order to collect a large enough sample size for comparison of the pre-
protocol/no nerve block patient sample. The IRB approval was requested until 
January 2019 to ensure complete data retrieval.  
• Audits for the retrospective data of the pre-protocol/no nerve block patient 
sample occurred within the same timeframe.  
• The monthly data will be analyzed and turned around to both the orthopaedic 
CNS, the othopaedic CNL, the orthopaedic nurse navigator, the orthopaedic unit 
nurse manager, the Clinical Service Director, and the trauma CNS for review.  
6. Dissemination of final project report by March 25th, 2018.  
Following data collection and analysis, the final strategy involves sharing local 
knowledge with key stakeholders to inform them about how care quality has changed as a 
result of protocol implementation (Powell et al., 2015). Sister organizations and other local 
organizations may build on the success or general knowledge of this nerve block protocol 
to promote care quality in their hip fracture patients.  
• Disseminating results to ED, PACU, OR, OU and other pertinent providers and 
administrators via email or in person by March 25th, 2019.  
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Measures 
Measurement tools and indicators include electronic health record data on: (1) 
Demographics of hip fracture patients (age, sex, race); (2) Hip fracture post-surgical readmission 
rates to the ED within 30 and 90 days; (3) Hip fracture mortality rates in the hospital; (4) Pre-
operative and post-operative Numeric Pain Scale or Visual Analog pain scores; (5) Pre-block and 
post-block Numeric Pain Scale scores; (6) Time from admission to the ED to administration of a 
nerve block; (7) Time from admission to the ED to the OR (preoperative waiting time); (8) Time 
from block administration to the OR; (9) Number of preoperative opioid analgesics used in 
morphine milliequivalents (MME); (10) Number of postoperative opioid analgesics used in MME; 
(11) Length of patient stay; (12) Cost of inpatient treatment and stay; (13) Incidence of pneumonia; 
(14) Incidence of delirium; (15) Incidence of unexpected intensive-care unit transfer; (16) Whether 
the nerve block was given/refused; and (16) Patient discharge destination. 
Data Collection Procedures 
In order to ensure the safety and privacy of participants and research data, patient names 
and MRNs did not leave the premises of the organization’s computers. The DNP student was the 
lead data collector. This collection was overseen by the orthopaedic CNS at the organization (see 
Appendix J). The DNP student utilized REDCap software at the site to encrypt the data and ensure 
patient privacy. Pertinent data was obtained with the assistance of the Clinical Information 
Specialist and Trauma CNS. The only patient demographic data collected for entering into the 
REDCap encrypted software included: patient age, sex, and race.  
The other outcome indicators are numeric variables that did not risk identifying the patient. 
For instance, each of the data outcomes were numerically coded and did not involve protected 
health information (i.e. Sex: 0=Male, 1=Female; Race: 0=Caucasian, 1=African American, 
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2=Hispanic, 3=Other; Hip fracture readmission: 0= no readmission in 30 days, 1=readmission in 
30 days). Patient chart information did not leave the organization’s campus. Only the data relating 
to the study outcomes were pulled, coded, and entered into REDCap prior to departure from the 
organization. This ensured security of protected health information and eliminated the potential for 
such information to be deliberately or unintentionally discovered. Data collection occurred weekly 
at the organization and ended in February 2019.  
Data Management   
 Collected data relevant to the patient outcome measures were stored in REDCap. The 
original patient charts were kept within the organization’s EHR system and did not depart from the 
campus databases. This data will be available to the organization for review and audit per the 
designated 7 years after conclusion of this project. The REDCap data was exported to and 
analyzed by a Grand Valley State University statistics graduate student.   
Analysis  
 The procedure for analysis of the current state of hip fracture pain management included 
recording of the aforementioned measurement indicators. In order to evaluate the preoperative 
waiting time, a dataset of patient transfers was manually reviewed. The time in hours was then 
quantified into a variable that could be processed into REDCap. Based on the quantified 
preoperative times, each patient’s preoperative pain score was then manually extracted from the 
data set. Once the delineation between preoperative and postoperative periods was outlined, the 
length of stay, postoperative patient numeric pain score, and postoperative opioid analgesic use 
were also calculated. The term “morphine milligram equivalents” (MME) accounts for differences 
in opioid drug type and strength by equating its dose in milligrams of morphine (CDC, 2017). 
MMEs were calculated using American Pain Society (2016) CDC (2016b) conversions (see 
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Appendix I). Oral medications were converted to MME with the oral morphine conversion factor. 
Intravenous (IV) medications were converted to MME with the IV morphine conversion factor. 
The graduate statistics student transferred the de-identified data from the exported REDCap 
file to the SAS statistical software for data analysis at Grand Valley State University. Outcome 
evaluation underwent inferential statistic testing through independent samples t-test. Assuming that 
the data fits a normal distribution, this method tested for significance between the two independent 
patient groups (no nerve block vs. nerve block) and for organizational compliance with the 
protocol. The outcome measures are displayed later as charts and graphs for presentation.  
Resources & Budget 
 The financial justification for this project should be noted (see Appendix K). So far, the 
calculated cost of in-kind mentoring of the organization’s CNS was forty hours, which totals 
$1,920 (Salary.com, 2018a). In terms of the nerve block kits, there is one kit stocked on the 
intensive care unit and three kits stocked in the ED. The items in each kit all could be used when a 
nerve block is administered. The contents of each kit total $30.95. Extra emergency supplies 
outside of the kit, but kept on the aforementioned units, include one bag of lipids ($9.12) and one 
continuous nerve stimulator kit ($51.59). Four kits ($123.80) and the additional extra emergency 
supplies ($242.84) would total $366.64.  
The organization decided to use the ultrasound-guided (USG) technique for administration. 
The USG technique has shortest time to onset of action, requires the least amount of local 
anesthetic, and has fewer complications compared to the other administration methods (Bates, 
Rhodes, & Amini, 2015).  
Two common procedural (CPT) codes are needed for nerve block administration. The CPT 
code 76942, which is for Ultrasonic guidance for needle placement, has a facility price in 
Michigan of $32.50 (CMS, 2018a). The second CPT code 64447, which is for a single femoral 
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nerve block injection, has a facility price in Michigan of $67.99 (CMS, 2018b). An 
anesthesiologist earns approximately $176.00 per hour (Salary.com, 2018b). It would therefore 
cost $44.00 for the fifteen minutes needed to administer the block. Narcotic cost savings would be 
negligible, according to the organization’s Clinical Pharmacy Services Program Director and 
Manager (see Appendix L).   
The three DRGs used interchangeably for hip fractures have an estimated operating room 
supply cost of $2500 per hip fracture case (XXX, 2018). The cost of the procedure itself will not 
change, which varies from $18,294.49 to $38,640.43 for the Grand Rapids and Muskegon area 
(Blue Cross Blue Shield, 2015). The projected cost for length of stay in a non-profit organization 
in Michigan is $2,298.00 (Kaiser Family Foundation, 2018). The organization provided the cost of 
$405.00 per day for an OU unit, and so these approximations were used for estimation.  
Usual length of stay for hip fractures 50 years and older is approximately 5.6 days 
(Basques, Bohl, Golinvaux, Leslie, Baumgaertner, & Grauer, 2015; Nikkel, Kates, Schreck, 
Maceroli, Mahmood, & Elfar, 2015). However, the organization’s trauma CNS reports that the 
average length of stay for their hip fracture patients was 3.89 days in 2017. This includes all hip 
fractures, regardless of whether they had surgery.  
Shortening the time from ED admission to surgery can reduce length of hospital stay (LOS) 
by one full day (Basques et al., 2015). This protocol may result in LOS cost savings due to its 
expedited pre-surgical pathway and the nerve block to mitigate pain and narcotic adverse 
reactions. Reduction in LOS is calculated by adding the cost of one day of care with the 
reimbursement for the nerve block procedure. For reduction in LOS of one day, hip fracture care 
costs are reduced from $1,575.45 to $1,170.45. Using the 146 operable hip fractures in 2017, this 
translates into a projected annual cost savings of $73,801.54.  
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Timeline  
 Utilization of Rosswurm and Larrabee’s Utilization of Rosswurm & Larrabee’s Model for 
Evidence-Based Practice Change (1999) provides the best approach to effectively implement a 
preoperative nerve block protocol for hip fractures.  
1. Assess need for change in practice. Meetings with key stakeholders began on April 
25, 2018. The DNP student met with the aforementioned key stakeholders of the 
organization between April and September 2018 to conduct an organizational 
assessment and a SWOT analysis assess the factors that would positively or negatively 
impact the nerve block protocol started in April 2018.  
2. Link problem with interventions and outcomes. The problem of preoperative hip 
fracture pain management was identified. The DNP student reviewed the literature for 
the preoperative nerve block efficacy in hip fracture patients.   
3. Synthesize best evidence. The review found that the local, single injection nerve 
blocks as a means of reducing preoperative pain and opioid analgesic use was at least 
moderately effective. Therefore, the previously enacted protocol was justified by 
research.  
4. Design an evaluation of the practice change. The DNP student created a plan for 
evaluation and analysis of the data collected during this quality improvement project. 
This included a data dictionary and collection tool in REDCap that reflects the outcome 
measures of interest. This program de-identified sensitive patient information. Data 
analysis occurred with the assistance of a Grand Valley State graduate statistics student. 
5. Evaluate the practice change. Weekly audits started on January 7, 2018, following 
Grand Valley State University and the organization’s IRB approvals. Data was 
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collected for the length of the intervention trial and analyzed to verify whether the 
practice change was successful in meeting the desired outcome indicators. Data 
collection ended in February 2018. Staff and peer feedback, cost, and benefits and risks 
were also taken into consideration at each weekly audit and during unit meetings in 
order to evaluate the effectiveness of the change. 
6. Integrate data that supports this change. Following the end of this quality 
improvement project, staff and organizational buy-in will help with future protocol 
revision and data analysis. The EHR order sets and standards of care for all hip fracture 
surgical candidates admitted to the organization will also help sustain this practice 
change.  
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Project Result Overview 
Approach Modifications 
During the process of data medical record review, additional patient characteristics were 
identified that were not delineated in the original project proposal. In the spirit of continuous 
quality improvement, the project was modified to accommodate: a change in patient date ranges 
for each collection group, inclusion and exclusion criteria for additional patient characteristics, and 
additional data measures.  
Per preference from the organization, the DNP student used the REDCap-encrypted 
program instead of an Excel spreadsheet for data collection. The REDCap data dictionary was then 
modified from the original data dictionary to reflect the aforementioned changes. The student met 
with and developed this plan in collaboration with the site mentor and project advisor. These 
modifications fell within the parameters of the original IRB approvals from the organization and 
Grand Valley, as they just expanded upon the original outcomes outlined in the project proposal 
(see Appendix M). The project was modified as follows: 
Timeframe changes. Once the DNP student was granted access to the electronic charts, it 
was discovered that there were a number of preoperative nerve blocks administered to patients 
within the month of March. Additionally, due to the timeframe to submit the data for analysis, the 
timeframe of evaluation was reduced from 9 months to 7 months for the pre-nerve block and nerve 
block groups. Therefore, the timeframe for the pre-nerve block patients was shifted from the 
original June 1, 2017 – February 28, 2018 to August 1, 2017 – February 28, 2018. The timeframe 
for the nerve block group was then shifted from the original April 1, 2018 – December 31, 2018 to 
March 1, 2018 – September 30, 2018. This resulted in 50 patients in each group. 
Patient characteristics. Following initiation of medical record review, the extent of patient 
variability also required further definition. While reviewing the electronic patient charts, there 
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were several concerning patient diagnoses and medications that the DNP student and her advisors 
felt were not representative of the organization’s usual hip fracture population. In order to preserve 
the integrity and assumption of normality between the two groups, several exclusion criteria were 
added during the electronic chart review process.  
The original exclusion criteria included: non-operable patients, nerve block refusal, or a 
medical allergy to the nerve block medication. Additional exclusion criteria added during 
evaluation included: active cancer with chemotherapy and/or radiation treatment, diagnosis of 
generalized chronic pain, diagnosis of low back pain with routine use of prescribed narcotics, 
multi-trauma cases, current polysubstance abuse, and patients placed on comfort care while at the 
organization. Patients were still included if they had a diagnosis of low back pain and no narcotic 
use or used narcotics as needed per their medication list. Patients with cancer were also included if 
there was no evidence of active chemotherapy and/or routine narcotic use in the electronic chart.  
Data outcomes. While manually reviewing each chart, data outcome entries were 
expanded to include: a diagnosis of dementia; incidences of post-surgical 60-day readmission 
rates; pre and post-operative pain scores and reassessment scores for non-narcotic medications; pre 
and post-operative pain scores and reassessment scores at 24, 48, 72, and 96 hours of LOS; and 
pre-block and post-block pain reassessment scores. Additionally, separate labels for oral (PO) and 
intravenous (IV) narcotic medication were created for each narcotic intake data measure in order to 
more accurately report MME usage by patients. Pain scores and pain reassessment scores were 
included for non-narcotic medications, such as acetaminophen and cyclobenzaprine, in order to 
capture the full context of pain control. If there was no narcotic pain medication administered 
within a set time frame, a value of 0 was entered into REDCap. Patient pain reassessments that 
were marked as “sleeping” were not included in the reassessment score total and were assigned a 
value. Organization compliance with the nerve block protocol was also added as an outcome.  
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Project Results 
 Demographics. Following the application of the aforementioned timeframe changes and 
patient exclusion factors, 50 patients in each group met inclusion criteria for a total sample of 100 
patients (n=100). All 50 patients in the nerve block group received a nerve block in the 
preoperative period. Patient demographics were checked for normality (see Appendix N). Males 
(n=16; 32%) and females (n=34; 68%) were fairly evenly distributed across the pre-block patient. 
In the nerve block group, similar findings were seen with males (n=13; 26%) and females (n=37; 
74%). Additionally, the racial distribution of Caucasians (n=48; 96%), African Americans (n=1; 
2%), and Hispanic (n=1; 2%) patients in the pre-block group was equal in distribution to the 
Caucasians (n=48; 96%), African Americans (n=1; 2%), and Hispanic (n=1; 2%) patients in the 
nerve block group. Patients admitted in either group with a pre-existing diagnosis of dementia 
were also evenly split between the pre-block group (n=18; 36%) and the nerve block group (n=19; 
38%). In terms of age, the pre-block group ranged from 57 to 99 years (M=80.54; SD=9.30). In the 
nerve block group, age ranged from 60 to 100 years (M=82.80 years; SD=10.45).   
 Care service time periods. Timeframes for care service transitions were calculated using 
REDCap (see Appendix O). The mean time in hours from patient admission to the OR in both 
groups was 21.92 hours, but ranged from 3.60 hours to 68.37 hours (SD=10.05). The average time 
in hours from patient admission to nerve block administration was 4.80 hours in the nerve block 
group, but ranged from 0.78 hours to 24.95 hours (SD=4.69). Finally, the average time from nerve 
block administration to the OR in the nerve block group was 17.29 hours, but ranged from 0.27 
hours to 70.98 hours (SD=11.81).  
Narcotic use. Narcotic use in oral and IV MME was calculated for total narcotics used 
preoperatively, postoperatively, and at 24, 48, 72, and 96 hours of inpatient stay (see Appendix P, 
Tables 1-6, Figures 1-4). Both PO and IV narcotic use in either group underwent non-parametric t-
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testing because normality assumptions were not met. The preoperative oral MME consumed in the 
pre-block group ranged from 0.00 to 30.00 (M=5.80, SD=7.02). In the nerve block group, the oral 
MME intake ranged from 0.00 to 47.50 (M=7.40, SD=10.77) (p=0.80). The preoperative IV MME 
consumed in the pre-block group ranged from 0.00 to 36.70 (M=9.65, SD=8.41). In the nerve 
block group, the intake of IV MME ranged from 0.00 to 30.00 (M=8.44, SD=8.14) (p=0.39).  
The postoperative oral MME consumed in the pre-block group ranged from 0.00 to 142.50 
(M=30.68, SD=32.97). In the nerve block group, the intake of MME or oral narcotics ranged from 
0.00 to 95.00 (M=21.10, SD=22.13) (p=0.23). The postoperative IV MME consumed in the pre-
block group ranged from 0.00 to 28.00 (M=1.91, SD=4.57). In the nerve block group, the intake of 
IV MME ranged from 0.00 to 16.00 (M=0.91, SD=2.84) (p=0.10).  
At 24 hours of inpatient stay, the average amount of oral MME consumed in the pre-block 
group (N=50) and the nerve block group (N=50) was 7.45 and 6.80, respectively (p=0.27). At 48 
hours of inpatient stay, the average amount of oral MME consumed in the pre-block group (N=49) 
and the nerve block group (N=48) was 13.77 and 9.27, respectively (p=0.42). At 72 hours of 
inpatient stay, the average amount of oral MME consumed in the pre-block group (N=36) and the 
nerve block group (N=34) was 12.85 and 7.94, respectively (p=0.33). At 96 hours of inpatient stay, 
the average amount of oral MME consumed in the pre-block group (N=14) and the nerve block 
group (N=17) was 10.27 and 7.20, respectively (p=0.98).  
At 24 hours of inpatient stay, the average amount of IV MME consumed in the pre-block 
group (N=50) and nerve block group (N=50) were 10.51 and 8.48, respectively (p=0.19). At 48 
hours of inpatient stay, the average amount of IV MME consumed in the pre-block group (N=49) 
and nerve block group (N=48) were 1.35 and 0.63, respectively (p=0.11). At 72 hours of inpatient 
stay, the average amount of IV MME consumed in the pre-block group (N=36) and nerve block 
group (N=34) were 0.09 and 0.29, respectively (p=0.28). Finally, at 96 hours of inpatient stay, the 
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average amount of IV MME consumed in the pre-block group (N=14) and nerve block group 
(N=17) were 0.00 and 0.20, respectively (p=0.41).  
Data on the difference between narcotic use before and after nerve block administration 
could not be analyzed due variance in time periods from admission to block and block to the OR. 
Since the times varied so much among the nerve block group patients, there was unlikely to have 
reoccurring doses.  
 Pain levels. Pain levels, or ratings, were averaged and entered into REDCap. Data analysis 
compared pain levels over designated time periods via non-parametric t-tests. For the pre-nerve 
block group, the average preoperative pain was 6.22/10 (SD=2.54) with an average reassessment 
level of 4.25/10 (SD=2.31). For the nerve block group, the average preoperative pain was 5.95/10 
(SD=2.00) with an average reassessment level of  4.52/10 (SD=2.44). During the postoperative 
period until discharge, the pre-nerve block group averaged a 4.37/10 (SD=1.83) with an average 
reassessment level of 2.88/10 (SD=1.92). In the nerve block group, the average pain level during 
the same time period was 3.78/10 (SD=1.71) with an average reassessment level of 2.45/10 
(SD=1.77). Therefore, both of the pre and postoperative comparisons were not significant (see 
Appendix Q, Figure 1). 
 Pain levels and pain reassessment levels were also averaged, entered into REDCap, and 
analyzed at 24, 48, 72, and 96 hours after surgery in both groups. During the first 24 hours after 
surgery, the average pain level in the pre-block group was 4.75/10 (SD=1.89) with an average 
reassessment level of 3.36/10 (SD=2.08). For the nerve block group, the average pain level was 
4.11/10 (SD=1.75) and average reassessment level was 2.69/10 (SD=2.03) during the same time 
period. This does not represent a statistically significant change. 
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 The average pain level 48 hours after surgery in the pre-block group was 4.27/10 
(SD=2.08), with an average reassessment level of 2.84/10 (SD=2.13). During the same timeframe, 
the nerve block group average pain level was 3.57/10 (SD=2.03) and average reassessment level 
was 2.21/10 (SD=1.97). At 72 hours after surgery, the average pain level of the pre-block group 
was 3.71/10 (SD=2.08) and the average pain reassessment level was 2.37/10 (SD=2.18). For the 
nerve block group, the average pain was 3.67/10 (SD=2.11) and average pain reassessment was 
2.64/10 (SD=2.22). Finally, 96 hours after surgery saw the pre-block group with an average pain 
level of 3.99/10 (SD=1.85) and reassessment of 2.88/10 (SD=1.92). For the nerve block group, the 
average pain level was 3.51/10 (SD=2.60), with an average reassessment pain level of 2.35/10 
(SD=2.24). These do not represent statistically significant changes (see Appendix Q, Figure 2). 
 The efficacy of the nerve block on preoperative pain levels was calculated using a paired t-
test comparing the difference in the average pain level before nerve block administration and the 
average pain level after nerve block administration (see Appendix Q, Figure 3). There was a 
statistically significant average reduction of 2.20/10 (SD=1.96) for patients (p<0.0001).  
 Length of stay. Overall, the intervention did not have a clinically significant effect on 
length of stay (see Appendix R). The duration of patient stay for the pre-block group ranged from 
1.91 days to 27.75 days, with an average of 4.61 days (SD=4.13). The duration of stay in the nerve 
block group ranged from 1.64 to 27.44 days, with an average of 4.34 days (SD=3.63) (p=0.90). 
This represents a reduction in length of stay by 6.51 hours, or 27% of the 24-hour day. 
 Cost savings. The nerve block group saw a reduction in length of stay by 6.51 hours. The 
projected cost of patient stay, including the cost of the procedure and an anesthesia consult, totals 
$2,279.69 at 4.61 days. However, the adjusted care cost for patient stay, including reimbursement 
reductions and new costs from a 6.51 hour stay reduction, totals $1,883.55. This results in a 
$57,836.44 annual cost savings for the organization as a result of the nerve block protocol.  
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Secondary outcomes. Secondary outcomes included incidence of pneumonia, incidence of 
delirium, unplanned transfer to the intensive care unit, readmissions, location of discharge, and 
mortality. Incidences of pneumonia did not differ between the two groups, with 1 patient in each 
group having a diagnosis of pneumonia upon discharge. There was also only 1 unplanned transfer 
to the intensive care unit in the nerve block group, but this transfer was unrelated to the nerve 
block. In terms of delirium, the nerve block did produce a reduction in episodes of delirium, but it 
was not statistically significant (p=0.10). The nerve block also did not reduce the incidence of 
delirium in patients with diagnosis of dementia present on admission (see Appendix S, Table 1).  
 There were 4 readmissions each in the pre-block and nerve block groups. In the pre-block 
group, one 30-day and one 90-day readmission were related to the hip fractures, while the other 
two were pertained to another medical problem. In the nerve block group, there was one 90-day 
readmission related to the patient falling on the surgically corrected hip again. The other 
readmissions were related to other comorbidities. The majority of the patients were discharged to 
subacute rehabilitation, followed by discharge to home with home health and to the home with 
outpatient physical therapy (see Appendix S, Table 2). There was one death in the nerve block 
group, but this was unrelated to the block. It was sudden so the patient was not placed on hospice.  
 Organization compliance. There were 112 total patients admitted to the organization with 
a hip fracture during the 7 month period of the initial nerve block protocol administration. 
Although only 50 patients met inclusion criteria for the nerve block group, 72 out of the 112 
patients received a nerve block within the preoperative period. Organization compliance with the 
protocol was therefore 64% for the first 7 months of protocol implementation. After reviewing the 
trauma registry data that was available from October 1, 2018 to December 31, 2018, there were 41 
hip fracture patients, of which 30 received preoperative nerve blocks. Compliance therefore 
increased to 73% in the 3 months following the timeframe for the DNP student evaluation.  
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Discussion  
 Overall, the data indicates that there are no statistically significant reductions in oral and IV 
narcotic use for total narcotics used preoperatively, postoperatively, and at 24, 48, 72, and 96 hours 
of inpatient stay. There was also no statistically significant reduction in patient length of stay or 
patient adverse effects, such as incidence of pneumonia, delirium, and unplanned transfer to the 
intensive care unit. Patient pain levels and reassessment levels between both groups were often 
comparable as well. The only statistically significant finding was the preoperative reduction in 
pain levels following nerve block administration. Due to variance in time of preoperative block 
administration, narcotic difference could not be calculated and the correlation between reduction in 
pain level and narcotic use could not be determined.  
Although there were no statistically significant values, there were some clinically 
significant reductions in pre and postoperative intravenous narcotic use, postoperative oral narcotic 
use, and episodes of delirium. However, the data still does not indicate that there is a direct 
association between administration of the nerve block and the anticipated outcomes. Possible 
reasons for differences between the anticipated and observed results includes sample size, 
compliance rate, and variance in time of preoperative nerve block administration. Stricter control 
over these factors may lead to outcomes consistent with current literature. However, the literature 
does not define the most effective time to administer a preoperative nerve block. This could be an 
organization-specific intervention that requires future research. Overall, these changes could 
produce more effective, safer pain control and increased cost savings for the organization. 
Strengths of this project include the detailed electronic chart review completed by the DNP 
student to compile fifty data measures for collection on each patient. However, due to the quality 
improvement and retrospective nature of this project, the DNP student was unable to influence the 
processes that impacted this data.   
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Limitations  
The factors that limit internal validity of this project are the small sample size of the patient 
population, the lack of time standardization for nerve block administration, and the current 
organization compliance with the protocol. Due to the retrospective and non-research nature of this 
project, such factors could not be controlled by the DNP student during evaluation. Additionally, 
no multiplicity adjustments were used for data outcomes. Future efforts to minimize limitations 
should center around sampling a larger homogenous population, as several results were trending 
towards significance with this project’s current sample size. Future efforts should also focus on 
greater organization compliance to the nerve block protocol to minimize variance between care 
transition times and nerve block administration.   
Conclusion  
Hip fractures are a debilitating injury that typically requires surgery. One of the most 
important aspects of hip fracture management is pain control, especially in the preoperative period. 
Current standards of practice primarily reflect an opioid model of analgesia, but these medications 
are associated with dangerous adverse effects. Recent literature highlights the success of local, 
single injection nerve blocks to aid in preoperative pain management. In accordance with the 
literature, the orthopaedic physicians at the organization implemented a preoperative, single 
injection nerve block protocol for hip fracture patients in March of 2018. However, this protocol 
had not yet been evaluated for organization compliance and patient outcomes.  
This quality improvement project investigated whether this protocol reduces hip fracture 
pain, use of systemic opioid analgesics, decreases incidence of adverse opioid effects, and reduces 
cost of care. Results were not statistically significant in reducing oral and intravenous narcotic use 
before (p=0.80; p=0.39) and after (p=0.23; p=0.10) surgical correction, nor was there statistically 
significant change in adverse effects (p=0.10) and length of stay (p=0.90) despite a 6.51 hour stay 
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reduction between groups. However, these results could be deemed clinically significant due to the 
implications of these reductions on patient care outcomes. A larger sample size could also produce 
more significant results. Protocol compliance was 66% over seven months. However, there was a 
statistically significant reduction in average preoperative pain levels following administration of 
the nerve block (p<0.0001).  
The results of this project were consistent with the literature; nerve block injection may 
reduce preoperative pain for patients with an operable hip fracture. Further investigation is needed 
to determine if narcotic use and length of stay could be impacted if time variability in nerve block 
administration were reduced and if protocol compliance were increased. 
Implications for Practice and Further Study in the Field 
 This DNP project encourages multiple practice implications. The literature supports the 
efficacy of single injection nerve blocks for hip fracture patients in the preoperative period. 
Although the results of the data outcome evaluation were not statistically significant, they are 
clinically significant. This presents an ongoing opportunity for the organization to improve upon 
protocol compliance and block administration standardization. A larger sample size could also be 
more beneficial in obtaining significant results. Currently there is no assigned individual tracking 
such outcomes, nor is there a designated process to ensure time standardization of preoperative 
block administration. Appointing an employee to continue monitoring patient data measures and 
organization compliance will provide expedited feedback turnaround.  
Revising the current protocol to include a time standardized administration of the nerve 
block may also help reduce the administration variability. Only a few articles in the literature 
review accounted for time from admission to block placement. The randomized control trial by 
Unneby et al. (2017) administered femoral nerve blocks within 82.9 minutes (+/- 95.7 minutes) of 
admission.  
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Another study by Haslam et al. (2013) evaluated timing of USG femoral nerve blocks in 
hip fracture patients when administered by ED physicians and residents. Although there were no 
direct time measures in their results, their block timing included administration immediately after 
X-ray confirmation of fracture, or immediately after medical assessment and triage. This highlights 
the need for improved timing of block administration upon admission to the ED, with possible 
future focus on training ED physicians, residents, NPs, and PAs to administer a USG nerve block. 
These changes could streamline processes and expedite pain control. The protocol may then 
produce the patient outcomes that originally led to the protocol introduction.  
Sustainability Plan 
 Continued stakeholder commitment, funding, and resource provision will help ensure that 
this nerve block protocol is sustainable. Although there are several internal weaknesses and 
external threats that may complicate protocol compliance, the organization’s internal strengths and 
opportunities may overcome these barriers. Data tracking sustainability beyond this quality 
improvement project may be successful if a key person is appointed to continue tracking cost and 
quality outcome measures. Additionally, unit feedback and cooperation may allow for more 
accurate and timelier EHR input if workload demands are balanced with patient care. 
Dissemination of Results 
 Dissemination of project results will first occur at the university in front of the DNP student 
project faculty and site advisor on March 25, 2019. The dissemination of results to the organization 
is pending, but will occur before April 27, 2019. The final draft of the scholarly quality 
improvement project with be uploaded to ScholarWorks© following final approval from the DNP 
student’s faculty advisor. Additionally, the DNP student could disseminate findings in the form of 
a literature publication in order to further current knowledge about preoperative, single injection 
nerve blocks in hip fracture patients.  
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Reflection on DNP Essentials 
 The American Association of Colleges of Nursing’s (AACN, 2006) eight essential DNP 
competencies helped guide the DNP student through this quality improvement project and towards 
graduation. These competencies serve as a foundation for DNP practice, and were developed and 
met during the evaluation of the organization’s nerve block protocol.   
Scientific Underpinnings for Practice 
 Scientific underpinnings for practice reflect the rigor of the doctoral education and the basis 
for nursing actions (AACN, 2006). The scientific basis of this quality improvement was rooted in 
the comprehensive literature review that validated the organization’s implementation and current 
use of the nerve block protocol. The patient data outcomes were also derived from the scientific 
literature. Additionally, evidence-based nursing theory and implementation models, such as the 
Model for Evidence-Based Practice Change (Rosswurm & Larrabee, 1999) guided the DNP 
student’s evaluation of the protocol in order to offer recommendations for improvement.  
Organizational and Systems Leadership 
 In order to affect change in organizational and policy arenas, the DNP student must be 
proficient in leading quality improvement and change sustainability (AACN, 2006). The DNP 
student demonstrated organizational and systems leadership by first conducting an organizational 
assessment of current practice needs (Burke & Litwin, 1992). This assessment validated the need 
for improved preoperative pain control in hip fractures. The DNP student therefore formulated a 
quality improvement project that evaluated current organization practices. The DNP student also 
demonstrated leadership through continuous, independent communication and inquiry with key 
stakeholders at the organization. Sensitivity to the organization’s culture and populations, 
including patients and providers, were also maintained during the project (AACN, 2006).  
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Clinical Scholarship and Analytical Methods 
 Scholarly nursing practice is a hallmark of DNP education (AACN, 2006). The DNP is 
equipped to translate evidence into practice at the patient-provider interface in order to produce 
improved health care outcomes (AACN, 2006). During this quality improvement project, the DNP 
student used a systematic, analytic approach to appraise current literature on the use of nerve 
blocks in hip fracture patients. The DNP student then designed a quality improvement project to 
evaluate the organization’s current practice. Utilization of technology and the assistance of a 
statistical consultant allowed the DNP student to successfully examine the effect of the 
organization’s current nerve block protocol and offer suggestions for improvement. 
Information Systems Technology 
 Use of information technology allows the DNP to assess, manage, and apply new 
knowledge related to quality improvement initiatives (AACN, 2006). The DNP student utilized the 
Cerner electronic health record system for manual chart review. The encrypted REDCap software 
was used to ensure privacy of patient data collection. Finally, the use the SAS software for data 
analysis allowed the DNP student to interpret the efficacy of the nerve block protocol. Legal and 
ethical issues were avoided through the approval of the organization’s and university’s IRBs.  
Advocacy for Health Care Policy 
 Addressing current care issues through policy development promotes increased access and 
quality of care, especially for those who consistently experience health care disparities (AACN, 
2006). This DNP project focused on hip fracture patients, who are typically considered a 
vulnerable population due to their age and comorbidities. The DNP student collaborated with key 
stakeholders to critically analyze and offer recommendations for the current preoperative nerve 
block protocol for this population. This project did not include policy change and the state, federal, 
or international level.  
FINAL DEFENSE  44
   
 
 
Interprofessional Collaboration 
 Interprofessional collaboration requires effective communication, partnering, and 
leadership in order to contribute to healthcare advancement (AACN, 2006). The DNP student 
worked collaboratively with physicians, a pharmacist, organization leadership, unit nurses an 
ancillary staff CNSs, CNLs, a statistician, and faculty advisors to develop and implement this 
quality improvement project. This collaboration allowed the DNP student to complete and 
disseminate the evaluation results of the current preoperative nerve block protocol in hip fractures.   
Clinical Prevention Population Health 
 Health promotion and disease prevention is a foundational principle of DNP clinical 
practice (AACN, 2006). This project focused on reduction of preoperative pain, reduction of 
narcotic use, reduction in adverse effects, and reduction in length of patient stay, which results in 
faster restoration of mobility. The student collected and evaluated data measures specific to hip 
fracture patients in order to provide recommendations for improved pain management in this 
population. The psychosocial and cultural components of care related to clinical prevention were 
included through application of the Theory of Symptom Management Model (Dodd et al., 2001). 
Advanced Nursing Practice 
 Advanced nursing practice includes advanced assessment and holistic treatment throughout 
a variety of care settings. These clinical experiences also help the DNP graduate comprehend the 
consequences of care decisions (AACN, 2006). For this quality improvement project, the DNP 
student created and sustained therapeutic partnerships with key organizational stakeholders in 
order to facilitate evaluation of the organization’s nerve block protocol. Additionally, the DNP 
student demonstrated advanced clinical judgment, systems thinking, and accountability through the 
development, evaluation, and dissemination of the current operational state and impact of the 
protocol.  
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Appendix A 
The Burke-Litwin Model of Organizational Performance and Change 
 
Figure 1. A model of organizational performance and change. Reprinted from “A Causal Model of 
Organizational Performance and Change,” by W. W. Burke and G. H. Litwin, 1992, Journal of 
Management, 18, 528. Copyright 1992 by Southern Management Association. 
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Appendix B 
SWOT Analysis of the ED, PACU, OR, and OU 
 
 
Strengths 
• Lean Six Sigma trained leadership 
• Culture of process improvement 
• Organization-wide teamwork 
• Magnet designation 
• TJC orthopaedic certifications 
• Hospital Quality Awards 
• Clinical Quality Awards for joint 
replacement 
• Nurse navigator 
• Joint classes 
Weaknesses 
• Lack of standardized protocol for 
communication and pain management 
for hip fractures 
• Providers meeting face to face  
• Staffing issues with anesthesiology, 
PACU, OU, RR 
• New provider unfamiliarity 
• Transitions of care 
• DRG codes 
 
Opportunities 
• Decrease use of opioids in midst of 
current opioid crisis 
• New evidence supporting nerve blocks 
• Established protocols for hip fractures 
from sister hospitals of parent 
company  
• Orthopaedic group merger 
Threats 
• Other local hospitals already 
implemented nerve block protocol for 
hip fractures 
• More competitive local branding 
• Insurance company preference 
• Centers for Medicaid and Medicare 
reimbursement measures 
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 Appendix C  
Search Terms Used for Literature Review in Databases 
 
Database PubMed CINAHL Cochrane Web of Science 
Keywords MeSH: Hip fractures, 
preoperative period, 
nerve block, pain 
management 
Nerve block, hip 
fracture, 
preoperative 
pain 
management 
Preoperative, 
nerve block, hip 
fracture, pain 
management 
Nerve block, hip 
fracture, 
preoperative, 
pain 
management 
Keyword 
Combinations 
Hip fractures AND 
Preoperative period 
AND nerve block 
 
Hip fractures AND 
Preoperative period 
AND Nerve block 
AND Pain 
management 
Hip fracture 
AND nerve 
block 
 
 
Preoperative 
AND nerve 
block AND hip 
fracture 
 
Nerve block 
AND hip 
fracture AND 
Pain 
management 
Preoperative 
AND nerve 
block AND hip 
fracture AND 
pain 
management 
 
“hip fractures” 
“nerve block” 
Search 
Results 
4 articles 14 articles  1 article 43 articles 
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Appendix D 
PRISMA Flow Diagram of Systematic Search 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram of search selection process. Adapted from “Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement,” by D. Moher, A. Liberati, J. 
Tetzlaff, D. Altman, and PRISMA Group. Copyright 2009 by PLoS Medicine. 
Records identified through 
database searching 
(n = 62) 
Records after duplicates removed 
(n = 50) 
Records screened 
(n = 50) 
Full-text articles assessed 
for eligibility 
(n = 27) 
Records excluded 
(n = 23) 
Full-text articles excluded, 
with reasons 
(n = 17) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =10) 
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Appendix E 
Table of evidence on the efficacy of nerve blocks 
Author (Year) 
Purpose 
Design (N) Inclusion 
Criteria 
Intervention vs 
Comparison 
Results Conclusion 
AAOS (2014) 
Compile a 
practice 
guideline based 
on current 
evidence to 
inform care of 
hip fractures in 
patients over 
age 65 
Systematic 
review of 
prospective 
randomized 
clinical trial 
studies (N=6 
studies) on 
regional 
analgesia for 
preoperative 
pain control 
Full article 
report of 
clinical study 
starting from 
1966; peer-
reviewed; 10 
or more patient 
per group; 
English; >50% 
patient follow-
up in studies 
with follow-up 
time points; 
Mean age of 
65 with hip 
fracture 
Comparison of 
preoperative 
administration of 
local anesthetic 
in fascia iliaca or 
femoral 
compartment on 
pain control vs. 
control group as 
measured by 
VAS.  
Efficacy: 
• Five out of the six (n=593 patients) 
high strength studies were limited 
to preoperative pain, sixth study 
included preoperative and 
postoperative 
• VAS scores indicated significant 
reduction in reported preoperative 
pain in 5/6 studies and 
nonsignificant reduction of pain in 
one study (Mean preop VAS score 
of placebo vs. FICB: 68.2 vs. 61.4, 
P=0.59) 
Safety of Intervention: 
• Type of administering provider 
(emergency physicians, 
anesthesiologists, orthopaedic 
surgeons) did not compromise 
patient safety 
• FICB 
o Hematoma, no adverse toxicity, 
no persistent paresthesia, 
decreased delirium 
• 3-in-1 nerve block 
o No difference from control in 
pulse, oxygenation, or 
respiratory rate during study 
• FNB 
Studies to date 
show reduced hip 
fracture 
preoperative pain. 
AAOS (2014) 
strength of 
recommendation is 
strong (4 stars) for 
use of preoperative 
regional analgesia 
in the form of 
nerve blocks. 
Further research 
needed on 
following 
outcomes needed: 
total opioid use 
pre-op, delirium 
incidence, and 
length of stay. 
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• No local, systemic complications  
Abou-Setta 
(2011) 
Review 
benefits and 
harms of 
pharmacologic 
and non-
pharmacologic 
hip fracture 
pain 
management 
Systematic 
review 
(N=83 
studies – 64 
RCTs, 5 non-
RCTs, 14 
cohort 
studies); 
Nerve block 
(N=29 
RCTs) 
RCTs, non-
RCTs, cohort 
studies, and 
case-control 
studies; No 
language 
restrictions; 
January 1990- 
December 
2010; Adults > 
50 y.o. with 
hip fracture; 
any pain 
management 
intervention; 
No specifics on 
pain method or 
point of time in 
care 
(preoperative, 
intraoperative, 
postoperative) 
Nerve block (3-
in-1, combined 
lumbosacral 
plexus, FICB, 
femoral, lumbar 
plexus +sciatic 
nerve, epidural 
and combined 
blocks) 
compared with 
placebo, 
standard care, or 
another nerve 
block.  
 
Efficacy: 
• 5 of 29 RCTs evaluated 
preoperative pain for nerve block 
vs. opioid analgesic control.  
• FICB 
o One study (n=48) found 
static (P<0.01) and dynamic 
(P=0.02) pain relief superior 
in FICB group compared to 
morphine + placebo FICB. 
Less mean total IM 
morphine consumption (0 
mg vs. 6 mg, P<0.01) with 
FICB 
• 3-in-1 preoperative nerve block 
o One study (n=40) VAS score 
2.0* at 20 minutes after 
block. VAS score 2.1* at 2 
minutes after control. 
(*p<0.001 vs. VAS score 
before FIC block or IV 
alfentanil). VAS score at 
positioning for spinal 
anesthesia lower compared 
to VAS of control (P=0.001) 
o One study (n=94) Time to 
best response/mean 
difference faster in block 
group (95% CI: -2.93 hours 
[-5.48 to -0.38 h]) and 
required less morphine per 
hour than control (95% CI: -
Systematic review 
not specific for 
nerve blocks, but 
one pain 
management 
method included in 
review. Pooled 
results for acute 
pain in nerve block 
studies were not 
reported due to 
significant 
heterogeneity. 
Moderate evidence 
to suggest efficacy 
of nerve blocks in 
reducing pain in 
hip fractures, as all 
nerve block types 
provided superior 
analgesia to no 
block or standard 
care.  
USG nerve block 
provided most 
significant effects 
of regional block.  
However, not 
enough well 
designed studies to 
be completely 
definitive.  
 
 
59 
0.68 mg/h [-1.23 to -0.12 
mg/h]) 
• FNB 
o One study (n=50) Pain with 
FNB less than control at 15 
min (P<0.05) and 2 hours 
(P<0.01) 
o One study (n=14) Pain with 
FNB less than control at 1 
hour (p<0.04), but not 
statistically significant at 4 
and 24 hours 
Safety of Intervention: 
• FICB 
o No adverse toxicity, no 
hematoma, no persistent 
paresthesia 
o Greater sedation in the 
morphine group (n=6) versus 
the FICB group (n=1) at 180 
minutes after block 
administration (P=0.05) 
• 3-in-1 nerve block 
o No difference from control in 
pulse, oxygenation, or 
respiratory rate during study 
• FNB 
o No local or systemic 
complications  
Fadhlillah 
(2017) 
Determine the 
analgesic 
Systematic 
review and 
meta-
analysis 
RCT in 
English; 
Patients 
>18y.o. with 
Single injection 
pre-operative 
FICB vs. 
standard 
Efficacy:  
• Acute pain significantly reduced 
with positioning and movement in 
FICB is superior in 
acute hip fracture 
pre-operative pain 
compared to 
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efficacy and 
safety profile 
of fascia iliaca 
compartment 
block (FICB) 
on preoperative 
pain in hip 
fracture 
patients 
(N=8 studies, 
645 patients) 
isolated 
traumatic hip 
fracture; 
Received 
single injection 
FICB 
preoperatively; 
No search date 
restriction 
applied 
preoperative 
systematic 
analgesia 
FICB (SMD) = -1.82 (95% CI: -
2.26 to -1.38, p<0.00001) 
• Acute pain was variable at rest with 
FICB (p=0.20) 
Safety of Intervention: 
• Reduced analgesia breakthrough 
(n=57 vs. n=73) 
• Reduced drowsiness/sedation (n=1 
vs. n=22) 
• Reduced desaturation (n=0 vs. n=4) 
• Reduced nausea and vomiting (n=3 
vs. n=7) 
• Both groups reported localized 
bruising (n=3) 
standard analgesia, 
especially during 
positioning and 
mobilization. FICB 
also is superior in 
safety and reduces 
reliance on 
systemic 
analgesics. 
However, only one 
study found low 
risk of bias. 
Guay (2017) 
Nerve block 
efficacy as 
preoperative or 
postoperative 
analgesia, or 
supplemental 
to general 
anesthesia in 
hip fractures 
Systematic 
review (N= 7 
trials, 322 
participants) 
RCTs 
comparing use 
of nerve blocks 
preoperatively, 
operatively, or 
postoperatively 
to no regional 
blockade 
added to 
general or 
neuraxial 
anesthesia as 
part of care 
provided for 
adults > 16 y.o. 
with hip 
fracture/proxi
mal femoral 
Participants 
randomized to 
peripheral nerve 
block (FNB, 
FICB, psoas 
compartment) 
using landmark, 
nerve stimulator 
or USG 
technique added 
to or not to 
general or 
neuraxial 
anesthesia for 
surgery vs. 
opioids 
 
Efficacy: 
• Five studies evaluating single 
injection nerve blocks (n=123) 
compared to opioid analgesia 
(n=122) showed decrease in opioid 
consumption favoring nerve 
blocks. SMD -0.73 (95% CI: -1.01, 
-0.44) 
• Out of three studies evaluating pain 
at rest 30 minutes after single block 
injection placement, two studies 
demonstrated reduction in pain 
favoring block. SMD -1.39 (95% 
CI: -2.11, -0.66) and SMD-1.36 
(95% CI: -2.04, -0.68), 
respectively. 
• Only one single injection study did 
not favor regional block efficacy, 
Regional blockade 
reduces pain on 
movement within 
30 minutes after 
block placement 
and reduces opioid 
consumption.  
 
 
61 
fracture; From 
1966 to 2016 
but pre-block pain scores were 
significantly higher in this group.  
Safety of Intervention: 
• No trials reported major 
complications 
• More data needed to determine 
impact on mortality 
 
Riddell (2016) 
Update 
evidence from 
review by 
Abou-Setta 
(2011) on the 
use of FNBs in 
the ED for 
managing hip 
fracture pain in 
the elderly.  
Systematic 
review (N=7 
studies) 
 
RCTs 
published 
between 
December 
2010 to May 
2014 to serve 
as an update to 
Abou-Setta 
(2011); About-
Setta (2011) 
reference list 
also used; 
Use of femoral 
nerve block in 
ED settings 
(pre-op) to 
treat hip 
fractures; 
>65 y.o.; 
pain and 
analgesic 
consumption 
Femoral nerve 
block vs. placebo 
control (opioid 
or ‘standard 
care’ analgesic) 
Efficacy: 
• Four studies evaluated single 
femoral nerve block injections: 
o FNB 
§ 1 study (n=50) Pain 
with FNB less than 
control at 15 min 
(P<0.05) and 2 hours 
(P<0.01) 
§ 1 study (n=14) Pain 
with FNB less than 
control at 1 hour 
(p<0.04), but not 
statistically significant 
at 4 and 24 hours 
o 3-in-1 block 
§ 1 study (n=94) Time to 
best response/mean 
difference faster in 
block group (95% CI: -
2.93 hours [-5.48 to -
0.38 h]) and required 
less morphine per hour 
than control (95% CI: -
0.68 mg/h [-1.23 to -
FNBs appear to be 
effective in 
managing acute 
pre-operative hip 
fracture pain in the 
elderly. Meta-
analysis could not 
be conducted due 
to study 
heterogeneity. 
Heterogeneity 
encountered in 
procedure type of 
femoral block 
placement and 
methods used to 
assess pain (VAS 
vs. NRS). Only 1 
study did not have 
a high risk of bias. 
 
 
62 
0.12 mg/h]) 
§ 1 study (n=36) showed 
significant reduction in 
NRS scores 4 hours 
post-block (P<0.001) 
and greater overall pain 
relief measured by 
summed pain intensity 
difference of 11.0 
(IQR=4.0 to 21.8) in 
block + morphine group 
vs. 4.0 (IQR=-2.0 to 
5.8) in sham 
injection/placebo + 
morphine group 
(P=0.001). 
Safety of Intervention: 
• 3-in-1 block  
o No difference in adverse events 
between groups in 1 study 
(n=36) 
• FNB 
o No local or systemic 
complications  
Ritcey (2016) 
Investigate if 
pre-operative 
nerve blocks 
result in 
reductions in 
pain, parenteral 
opiate use, and 
complications 
Systematic 
review of 
RCTs (N=9 
studies); 
Meta-
analysis 
could not be 
conducted 
RCTs from 
1946 to 2014;  
> 16 y.o. with 
acute hip or 
femoral neck 
fracture; 
Single 
injection FNB, 
Single injection 
nerve blocks 
(Single injection 
FNB, 3-in-1 
FNB, or FICB) 
with standard 
pain 
management 
Efficacy: 
• Two studies utilized FNB (n=40), 
Four studies utilized 3-in-1 FNB 
(n=97), and three studies used 
FICB (n=147) 
• One study used ultrasound 
guidance (USG), Five used 
landmark technique, and three 
studies used nerve stimulator 
Regional nerve 
blocks are at least 
as effective and 
potentially superior 
in reducing pain 
compared to 
standard pain 
management.  
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compared to 
standard pain 
management in 
hip fractures 
due to study 
heterogeneity 
3-in-1 FNB, or 
FICB; 
Pre-operative 
injection; 
Pain score 
reduction 
recorded 
• One study was double-blinded and 
USG (n=36) found: 
o Reduced 11-point numerical 
rating scale (NRS) scores at 4 
hours (p<0.001).  
o Median summed pain intensity 
difference (SPID) was 11.0 
(IQR = 4.0 to 21.8) in FNB 
group vs. 4.0 (IQR = -2.0 to 
5.8) in placebo group over 4 
hours 
o Patients in placebo group 
received more IV morphine 
than FNB group (5.0 mg, 
IQR= 2.0 to 8.4 mg vs. 0.0 
mg, IQR= 0.0 to1.5 mg) 
Safety of Intervention: 
• None of the studies reported any 
immediate complications 
• One double-blinded USG study 
found no difference in adverse 
events between groups 
• Unable to conclude whether 
reduced IV opiate use also resulted 
in reduced adverse effects due to 
under-reporting in most of the 
studies 
Sample sizes were 
small in all RCTs, 
ranging from 33-
154 participants. 
Lack of double-
blinding in six out 
of nine studies 
resulted in 
moderate to high 
risk of bias. Only 
one study had 
overall low risk of 
bias. 
Scurrah (2018) 
Examine 
current pain 
management 
for hip 
fractures in the 
Narrative 
review of 
RCTs (N=8) 
Level 1 and 
Level 2 
Clinical trials, 
clinical audits, 
review articles, 
and meta-
Regional nerve 
blocks for acute 
hip fracture pain 
vs. standard care, 
opioid placebo 
Efficacy: 
• Regional nerve blocks reduce hip 
fracture pain on movement within 
30 min of block placement (Guay, 
2017) 
Nerve blocks 
reduce acute pain, 
opiate consumption 
and delirium. 
Nerve blocks for  
hip fractures 
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elderly, 
especially role 
of regional 
nerve blocks 
analyses in 
English; >18 
y.o.; From 
2007-May 
2017 
• FICB, FNB, psoas compartment, 
and combined nerve block 
provided superior analgesia to 
placebo or ‘standard care’ in hip 
fractures (About-Setta, 2017) 
• Preoperative single injection 
regional nerve blocks reduce 
consumption of opioids in hip 
fractures and opioid side effects 
o One study (n=48) found 
less mean total IM 
morphine consumption (0 
mg vs. 6 mg, P<0.01) with 
FICB versus morphine + 
FICB placebo 
o One study (n=161) found 
33-40% reduction in 
parenteral morphine 
equivalent consumption and 
reduction in opioid side 
effects (3% vs. 12.4%, 
P=0.03) 
o FICB in one study (n=69) 
reduced mean opioid use 
from 6.2 mg to 2.0 mg 
(P=0.01) and opioid 
overdose incidence (7.2% 
to 0%, P=0.001) 
Safety: 
• One study in inpatient mortality 
with nerve block: 5.5% vs. 15% 
(P=0.0024) 
should be 
integrated into 
routine pain 
management 
protocols. 
Additional research 
is needed on cost 
savings of nerve 
blocks on length of 
stay, mortality, 
morbidity, and 
quality of life.  
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• No statistically significant 
difference in cardiac complications, 
deep vein thrombosis, pulmonary 
embolism, nausea and vomiting, 
respiratory infection, stroke, 
surgical wound infection, or 
urinary tract infection (Abou-Setta, 
2011) 
• In FICB study (n=48), greater 
sedation in the morphine group 
(n=6) versus the FICB group (n=1) 
at 180 minutes after block 
administration (P=0.05) 
• USG technique improves safety 
and efficacy of nerve blocks  
o One study found greater 
sensory loss in medial thigh 
with USG vs. “two-pop/loss 
of resistance” technique” 
(95% vs. 60%) and complete 
sensory loss in anterior, 
medial, and lateral thigh 
(82% vs. 47%) 
• Junior staff, paramedics, and new 
residents can be trained to 
effectively administer nerve blocks 
without increase in complications 
Steenberg 
(2018) 
Investigate 
FICB benefit 
and adverse 
events in pre-
Systematic 
review and 
meta-
analyses of 
RCTs (N=8) 
and quasi-
RCTs and 
quasi-RCTs 
from database 
inception to 
2016; 
Comparison 
FICB with non-
intervention, 
placebo, 
paracetamol, 
NSAIDs, opioid, 
Efficacy: 
• Two studies demonstrated 
analgesic effect in FICB group in 
first 30 minutes (P=0.001 fentanyl 
control, P=0.047 morphine sulfate 
control). Only one study had 3 hour 
FICB has superior 
analgesic effect 
compared with 
opioids during 
movement, but not 
at rest. FICB had 
 
 
66 
operative hip 
fracture 
patients 
RCTs (N=3) 
(N=11 total) 
> 18 y.o. with 
hip fracture; 
Pre-operative 
administration; 
Studies 
published in 
peer-reviewed 
journals 
 
or other nerve 
blockades using 
visual analog 
scale (VAS) and 
NRS; 
Continuous 
catheter and 
single injection 
included but 
clearly 
delineated; 
Four (N=4) 
studies included 
opioids as 
control 
measurement, which was in favor 
of FICB (P=0.01) 
• During movement, three studies 
were in favor of FICB in first 30 
minutes (P=0.02), SMD 1.58 (95% 
CI: -2.90, -0.25). No difference at 
rest (P=0.15), SMD -0.59 (95% CI: 
-1.40,0.21) 
• Three studies reported mean dose 
of additional morphine for:  
o 4.11 mg (95% CI: 2.61,5.61) 
vs. 7.42 mg (95% CI: 
5.24,9.60) (P=0.03) 
o 0 mg (95% CI: 0,0) vs. 6 mg 
(95% CI: 5.38,6.62) (P<0.01) 
o 0 mg (95% CI: -1.24,1.24) vs. 
5 mg (95% CI: 2.20,7.80), 
(P=0.03) 
• Meta-analysis of two studies on 
request for additional opioids: 
o 245 min (95% CI: 2055,285) 
vs. 145 min (95% CI: 14.9, 
275) (P=0.12) 
o 516 min (95% CI: 437,594) 
vs. 270 min (95% CI: 
189,351) (P<0.01) 
o Total between studies: longer 
time for first request of 
additional analgesia in FICB 
group SMD 0.93 (95% CI: 
0.02,1.84) (P=0.05)  
• Meta-analysis of four studies: 
lower pre-operative 
additional opioid 
use and longer 
duration between 
block and first 
analgesic dose. 
N=3 RCTs were 
rated with low risk 
of bias and N=5 
RCTs had a high 
risk of bias. N=3 
quasi-RCTs also 
had a high risk of 
bias. Concern with 
heterogeneity of 
studies and under-
reporting of 
adverse effects.  
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o FICB had lower preoperative 
opioid analgesia SMD -1.89 
(95% CI: -3.63, -0.14) 
(P=0.03) 
• Compared to opioids at rest, the 
meta-analysis did not demonstrate 
a difference. 
Safety of Intervention: 
• Incidence rate of hematomas at 
injection site: 1.7% for articles 
included in the review 
• Eight cohort and retrospective 
studies (n=2179) in full text of the 
review cite 4 instances of 
anesthetic toxicity (risk of 0.18%) 
and 2 hematomas at the injection 
site (risk of 0.9%).  
Unneby (2017) 
Determine 
whether 
preoperative 
femoral nerve 
block 
administration 
reduced acute 
pain and opioid 
use in elderly 
patients, 
including those 
with dementia 
RCT (n=266 
patients) 
Patients >70 
years admitted 
to orthopaedic 
hospital ward 
for hip fracture 
prior to 
surgery; With 
or without 
dementia; 
Consent to 
treatment  
FNB + opioids 
(n=129) or 
conventional 
opioid treatment 
(n=137) effect 
on preoperative 
pain (VAS) and 
preoperative 
opioid 
consumption 
Efficacy: 
• Self-rated and proxy VAS pain 
scores decreased from baseline to 12 
hours in intervention group vs. 
control (P<0.001 and P=0.003, 
respectively) 
• Intervention group received 
significantly less opioids than 
control group (IV, 2.3 + 4 mg vs. 
5.7 + 5.2 mg, P<0.001; Oral, 2.1 + 
4.1 mg vs. 3.6 + 6.4 mg, P=0.017) 
• Patients with dementia in 
intervention group received less IV 
opioids compared to control group 
(2.1 + 3.3 mg vs. 5.8 + 5 mg, 
P<0.001) 
Before 
randomization, 
n=191 patients 
received opioids 
(IV or oral) in the 
ambulance or in the 
ED, which may 
account for lower 
VAS pain scores. 
However, FNB 
further reduced 
scores at 12 hours. 
Recommend nerve 
block 
administration 
performed in ED to 
 
 
68 
Safety: 
• No adverse events reported for 
FNB 
 
improve results of 
this study.  
Wennberg 
(2018) 
Evaluate 
current 
evidence 
surrounding 
emergency care 
for patients 
admitted with 
hip fracture, 
with focus of 
pain 
Integrative 
review 
(N=38 
articles: 34 
quantitative, 
4 qualitative) 
Double-blind 
RCTs to 
qualitative 
studies; 
Publish from 
1998 to 2017; 
Described 
chain of 
emergency 
care for hip 
fractures after 
falling; Age 
range not 
specified in 
methodology 
Regional nerve 
block vs. 
parenteral 
opioids, 
Multifactorial 
program impact 
on delirium, 
Experiences of 
physical pain, 
current practices 
of managing 
pain in hip 
fractures, 
Efficacy of fast-
track 
management 
system, TENS 
efficacy, 
Describe lived 
experiences of 
older adult in ED 
Efficacy: 
• Of 34 quantitative studies, only 
three rated as High quality, 
however one study evaluated 
single vs. continuous nerve block 
and one study evaluated nerve 
blocks vs. NSAIDs. This left one 
RCT that evaluated preoperative 
FICB compared to systemic 
morphine: 
o The study (n=48) found 
static (P<0.01) and dynamic 
(P=0.02) pain relief superior 
in FICB group compared to 
morphine + placebo FICB 
using 5 point Verbal ranking 
scale. Less mean total IM 
morphine consumption (0 
mg vs. 6 mg, P<0.01) with 
FICB 
Safety: 
• FICB 
o No adverse toxicity, no 
persistent paresthesia 
o Greater sedation in the 
morphine group (n=6) vs. the 
FICB group (n=1) at 180 
minutes after block 
administration (P=0.05) 
After evaluating 
the quantitative and 
qualitative 
evidence, the 
results indicate that 
nerve blocks can be 
effective in 
preoperative pain 
management for 
hip fractures. 
However, the paper 
presents with a 
majority of low-
level evidence 
according to the 
GRADE criteria.  
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Appendix F 
Theory of Symptom Management Model  
 
Adapted from “Advancing the science of symptom management,” by M. Dodd, S. Janson, N. 
Facione, J. Faucett, E.S. Froelicher, J. Humphreys … D. Taylor. Copyright 2001 by Journal of 
Advanced Nursing.  
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Appendix G 
\.  
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Figure 1. Adapted from “Hip fracture pathway,” by L. Zuckerman. Copyright 2017 by XXX. 
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Figure 2. Adapted from “Staff educational powerpoint: Fascia iliaca blocks and local anesthetics 
systemic toxicity (LAST),” by K.L. Johnson, A. Zeerip, and S. Veurink-Balicki. Copyright 2018 
by XXX. 
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Appendix H 
 
Adapted from “A model for change to evidence-based practice,” by M.A. Rosswurm and J.H. 
Larrabee. Copyright 1999 by Journal of Nursing Scholarship.  
 
 
 
 
 
 
 
 
 
 
FINAL DEFENSE   
   
 
 
74 
Appendix I 
Morphine Equivalent Conversions 
Medication Route of 
Administration 
Morphine 
Equivalent 
Conversion Factor 
HYDROmorphone 
(Dilaudid) 
Intravenous 0.15 mg 6.7 
Fentanyl Intravenous 10 mcg 0.1 
Oxycodone Oral 2 mg 1.5 
Acetaminophen-
HYDROcodone 
(Norco) 
Oral 1 mg 1 
Tramadol (Ultram) Oral 10 mg 0.1 
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Appendix J 
Letter of Agreement for Organization Advisor 
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Appendix K 
Budget and Projected Cost 
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Appendix L 
Cost of preoperative and postoperative narcotic medications included in order sets 
Medication Dose, Route, 
Frequency 
Pain Level 
Indication 
Numeric 
Scale 
Cost 
Tramadol (Ultram) 50 mg, Oral, q 4 
hours 
Moderate  
(4-6/10) 
$0.60/tab 
Acetaminophen-
HYDROcodone 
(Norco) 
5 mg/325 mg, Oral,  
q 4 hours 
Moderate  
(4-6/10) 
$0.17/tab 
Acetaminophen-
OxyCODONE 
(Oxycodone) 
5 mg, Oral, q 4 hours Moderate (4-
6/10) – 
Severe 
(7-10/10) 
$0.18/tab 
Morphine 1 mg, Intravenous,  
q 2 hours 
Severe 
(7-10/10) 
$1.63/syringe (syringe 
manufactured as 4 mg/1mL 
syringe, but charge would be 
the same for any dose up to 4 
mg) 
HYDROmorphone 
(Dilaudid) 
0.5 mg, Intravenous,  
q 4 hours 
Severe 
(7-10/10) 
$1.80/syringe (syringe 
manufactured as 1 mg/mL 
syringe, but charge would be 
the same for any dose up to 1 
mg) 
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Appendix M 
Institutional Review Board Approval
  
Figure 1. Institutional Review Board approval letter from the organization site. 
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Figure 2. Institutional Review Board approval letter from Grand Valley State University. 
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Appendix N 
Patient Demographics 
 Pre-Block Group Nerve Block Group 
Sample Size N=50 N=50 
Gender Distribution 
Male N=16 N=13 
Female N=34 N=37 
Race Distribution 
Caucasian N=48 N=48 
African American N=1 N=1 
Hispanic N=1 N=1 
Dementia Diagnoses N=18 N=19 
Average Patient Age 80.54 years 82.80 years 
 
 
 
 
 
 
 
 
FINAL DEFENSE   
   
 
 
81 
Appendix O 
Table 1. Care transition timeframes output using SAS MEANS output procedure.  
Care Service Timeframes in Hours 
Calculated Field N Mean 
Time 
SD Minimum Maximum 
Admission to OR Time 100 21.92 10.05 3.60 68.37 
Pre-Block 50 21.98 9.08 3.72 56.32 
Nerve Block 50 21.87 11.03 3.60 68.37 
Admission to Block Time 50 4.80 4.69 0.78 24.95 
Block to OR Time 50 17.29 11.81 0.27 70.98 
 
 
Figure 1. Care transition timeframes illustrated as a graphical output.  
 
 
0
10
20
30
40
50
60
70
80
Admission to OR Admission to Block Block to OR
Care Service Timeframe in Hours
Minimum Mean Maximum
FINAL DEFENSE   
   
 
 
82 
Appendix P 
Table 1. Preoperative oral MME patient intake 
Preoperative Oral MME  
 N Mean MME SD Minimum Maximum 
Pre-Block 
Group 
50 5.80 7.02 0.00 30.00 
Nerve Block 
Group 
50 7.40 10.77 0.00 47.50 
 p=0.80  
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2489.50).  
 
 
Figure 1. Preoperative oral MME intake. Box plots depicting entire data set for the Pre-block 
and Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve 
Block group. 
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Table 2. Preoperative intravenous MME patient intake 
Preoperative Intravenous MME  
 N Mean MME SD Minimum Maximum 
Pre-Block 
Group 
50 9.65 8.41 0.00 36.70 
Nerve Block 
Group 
50 8.44 8.14 0.00 30.00 
 p=0.39  
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2649.50).  
 
 
Figure 2. Preoperative IV MME intake. Box plots depicting entire data set for the Pre-block and 
Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve 
Block group. 
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Table 3. Postoperative oral MME patient intake 
Postoperative Oral MME  
 N Mean MME SD Minimum Maximum 
Pre-Block 
Group 
50 30.68 32.97 0.00 142.50 
Nerve Block 
Group 
50 21.10 22.13 0.00 95.00 
 p=0.23  
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2697.50).  
 
 
Figure 3. Postoperative oral MME intake. Box plots depicting entire data set for the Pre-block 
and Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve 
Block group. 
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Table 4. Postoperative intravenous MME patient intake 
Postoperative Intravenous MME  
 N Mean MME SD Minimum Maximum 
Pre-Block 
Group 
50 1.91 4.57 0.00 28.00 
Nerve Block 
Group 
50 0.91 2.84 0.00 16.00 
 p=0.10  
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2703.50).  
 
 
Figure 4. Postoperative IV MME intake. Box plots depicting entire data set for the Pre-block and 
Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve 
Block group.  
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Table 5. Oral MME intake at 24, 48, 72, and 96 hours of inpatient stay 
Total Oral MME Intake 
 N Mean MME 
24 Hours  
Pre-Block Group 50 7.45 
Nerve Block Group 50 6.80 
p-value 0.27 
48 Hours  
Pre-Block Group 49 13.77 
Nerve Block Group 48 9.27 
p-value 0.42 
72 Hours  
Pre-Block Group 36 12.85 
Nerve Block Group 34 7.94 
p-value 0.33 
96 Hours  
Pre-Block Group 14 10.27 
Nerve Block Group 17 7.20 
p-value 0.98 
Note. Outcomes for the Pre-block and Nerve Block groups analyzed through Wilcoxen Two-
Sample Test.  
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Table 6. Intravenous MME intake at 24, 48, 72, and 96 hours of inpatient stay 
Total Intravenous MME Intake 
 N Mean MME 
24 Hours  
Pre-Block Group 50 10.50 
Nerve Block Group 50 8.48 
p-value 0.19  
48 Hours  
Pre-Block Group 49 1.35 
Nerve Block Group 48 0.63 
p-value 0.11 
72 Hours  
Pre-Block Group 36 0.09 
Nerve Block Group 34 0.29 
p-value 0.28 
96 Hours  
Pre-Block Group 14 0.00 
Nerve Block Group 17 0.20 
p-value 0.41 
Note. Outcomes for the Pre-block and Nerve Block groups analyzed through Wilcoxen Two-
Sample Test.  
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Appendix Q 
 
Figure 1. The change in total preoperative and postoperative pain levels and reassessment levels. 
 
Figure 2. The change in pain levels and pain reassessment levels at 24, 48, 72, and 96 hours 
postoperatively and until discharge.  
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Figure 3. The change in reported pain levels following preoperative nerve block administration.  
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Appendix R 
Analysis of Variance for Length of Patient Stay 
Classified by Variable Group 
Group N Mean LOS (Hours)  
Pre-Block 50 110.74333 
Nerve Block 50 104.237667 
Wilcoxen Two-
Sample Statistic 
 2544.0000 
p-value 0.90 
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Appendix S 
Table 1. Secondary Patient outcome indicators. 
Secondary Patient Outcomes 
 N Total Delirium Pneumonia ICU Transfer 
Pre-Block  
Group 
50 11 1 0 
Nerve Block 
Group 
50 5 1 1 
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Table 2. Discharge location for patients across both groups.  
 
Note. “Pre” group represents the pre-block group; “Post” represents the nerve block group; “sar” 
represents subacute rehabilitation; “Other” is any discharge location.  
 
 
Figure 1. Discharge location as exhibited in a chart representation.  
